Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?

被引：2

作者：

Popovic, Djordje S. ^{[1
,2
]}

Patoulias, Dimitrios ^{[1
]}

Koufakis, Theocharis ^{[2
]}

Stavropoulos, Konstantinos ^{[2
]}

Karakasis, Paschalis ^{[3
]}

Ruza, Ieva ^{[4
]}

Papanas, Nikolaos ^{[5
]}

Rizzo, Manfredi ^{[6
]}

Doumas, Michael ^{[2
]}

机构：

[1] Univ Novi Sad, Med Fac, Clin Ctr Vojvodina, Clin Endocrinol Diabet & Metab Disorders, Novi Sad, Serbia

[2] Aristotle Univ Thessaloniki, Gen Hosp Hippokration, Propedeut Dept Internal Med 2, Thessaloniki, Greece

[3] Aristotle Univ Thessaloniki, Gen Hosp Hippokration, Dept Cardiol 2, Thessaloniki, Greece

[4] Riga Eastern Clin Univ Hosp, Dept Endocrinol, Riga, Latvia

[5] Democritus Univ Thrace, Univ Hosp Alexandroupolis, Diabet Ctr, Dept Internal Med 2, Alexandroupolis, Greece

[6] Univ Palermo, Sch Med, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy

来源：

JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2024年 / 38卷 / 08期

关键词：

Tirzepatide; Type; 2; diabetes; Normoglycemia; INSULIN GLARGINE; GLYCEMIC CONTROL; DOUBLE-BLIND; MANAGEMENT; PLACEBO; GLP-1; GIP;

D O I：

10.1016/j.jdiacomp.2024.108800

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We sought to determine whether treatment with tirzepatide in type 2 diabetes mellitus (T2DM) patients can increase the odds for achieving normoglycemia, compatible with glycated hemoglobin levels lower than 5.7 %. We demonstrated that treatment with tirzepatide versus control increased the odds for achievement of normoglycemia by >16 times.

引用

页数：3

共 50 条

[31] Tirzepatide: A Review in Type 2 Diabetes
Nicole L. France
Yahiya Y. Syed
Drugs, 2024, 84 : 227 - 238
[32] Bariatric surgery for the treatment of Type 2 diabetes: a step closer?
Chantziara, Klio
Laferrere, Blandine
Pi-Sunyer, Xavier
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (03) : 231 - 237
[33] Effect of Normoglycemia on the Disrupted Osteoblast Differentiation of Mesenchymal Stem Cells Induced by Type 1 and Type 2 Diabetes Mellitus
Weffort, D.
Adolpho, L. F.
Souza, A. T. P.
Freitas, G. P.
Lopes, H. B.
Oliveira, F. S.
Bighetti-Trevisan, R. L.
Pitol-Palin, L.
Matsushita, D. H.
Okamoto, R.
Beloti, M. M.
Rosa, A. L.
MOLECULAR BIOLOGY OF THE CELL, 2023, 34 (02) : 1247 - 1248
[34] Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not?
Patoulias, Dimitrios
Dimosiari, Athina
Fragakis, Nikolaos
FUTURE CARDIOLOGY, 2023, 19 (06) : 301 - 312
[35] Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus
Al Zweihary, Ali M.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
[36] Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity
Sardar, Muhammad Bilal
Nadeem, Zain Ali
Babar, Muhammad
CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (05)
[37] Diabetes Mellitus Type 2 and Drug Interactions
Linke, J.
Rost, K. L.
DIABETES STOFFWECHSEL UND HERZ, 2014, 23 (04): : 209 - 215
[38] An unusual case of drug-induced annular granulomatous vasculitis in a patient with rheumatoid arthritis and type 2 diabetes mellitus
Kubba, Faris
Aliyeva-Derraz, Pakiza
Gradassi, Alessandro Traniello
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I117 - I118
[39] Immunosuppressive drug-induced diabetes
Penfornis, A.
Kury-Paulin, S.
DIABETES & METABOLISM, 2006, 32 (05) : 539 - 546
[40] Drug-Induced Hyperglycaemia and Diabetes
Neila Fathallah
Raoudha Slim
Sofien Larif
Houssem Hmouda
Chaker Ben Salem
Drug Safety, 2015, 38 : 1153 - 1168

← 1 2 3 4 5 →